950596-59-5

Basic information

• Product Name: Erlotinib Impurity 22
• Synonyms: Erlotinib Impurity 22
• CAS NO: 950596-59-5
• Molecular Weight: 321.376
• Mol File: 950596-59-5.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: Erlotinib Impurity 22(CAS DataBase Reference)
• NIST Chemistry Reference: Erlotinib Impurity 22(950596-59-5)
• EPA Substance Registry System: Erlotinib Impurity 22(950596-59-5)

Safety Data

• Hazardous Substances Data: 950596-59-5(Hazardous Substances Data)

Upstream product

• 950596-58-4 2-amino-4,5-bis-(2-methoxyethoxy)-benzonitrile 
• 21511-55-7 (methoxymethylidene)dimethylammonium methyl sulfate 
• 99-50-3 3,4-Dihydroxybenzoic acid 
• 819813-71-3 3,4-bis(2-methoxyethoxy)-benzoic acid 
• 1418289-91-4 3,4-bis(2-methoxyethoxy)-benzamide 
• 236750-65-5 4,5-bis(2-methoxyethoxy)-2-nitrobenzonitrile 
• 80407-68-7 3,4-bis(2-methoxyethoxy)-benzonitrile 
• 4637-24-5 N,N-dimethyl-formamide dimethyl acetal 

Downstream Products

• 183321-74-6 erlotinib 
• 183319-69-9 erlotinib hydrochloride 

Relevant articles and documents

A erlotinib new impurity and its preparation method

The present invention discloses a new impurity related with erlotinib synthesis, and a preparation method thereof, wherein the new impurity is 3-(3-ethynyl-phenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4(3H)-imine. According to the present invention, the pre

An improved convergent approach for synthesis of erlotinib, a tyrosine kinase inhibitor, via a ring closure reaction of phenyl benzamidine intermediate

An improved convergent and economical method has been developed for the synthesis of erlotinib, a 4-anilinoquinazoline and an EGFR-tyrosine kinase inhibitor for treatment of non-small-cell lung cancer. The final two steps for the formation of this 4-anilinoquinazoline from suitable 2-aminobenzonitrile intermediate and 3-ethynylaniline were modified and were performed in a simple one-pot reaction. The ring-closing mechanism for the formation of erlotinib from the suitable formamidine intermediate and 3-ethynylaniline was investigated and determined to proceed via the formation of phenyl benzamidine intermediate rather than involving Dimroth rearrangement reported earlier. The new benzamidine intermediate was isolated for the first time and characterized. Copyright

A PROCESS FOR SYNTHESIS OF [6,7-BIS-(2-METHOXYETHOXY)-QUINAZOLIN-4-YL]-(3-ETHYNYLPHENYL)AMINE HYDROCHLORIDE

The present invention provides a process for synthesizing [6,7-bis(2-methoxyethoxy)quinazolin-4-yl]-(3-ethynylphenyl)amine hydrochloride (Erlitinib Hydrochloride) having the formula (I) comprising reacting 3,4-dihydroxy benzaldehyde with bromo derivative of ethyl methyl ether to obtain 3,4-bis(2-methoxyethoxy)benzaldehyde having formula (III). This is converted to give 3,4- bis (2-methoxyethoxy)-benzonitrile which on furthur nitration we obtain 4,5- bis (2-methoxyethoxy)-2-nitrobenzonitrile which on nitro reduction we get 2-amino-4,5-bis(2-methoxyethoxy)benzonitrile. Formylation of this compound yields N'-[2-cyano-4,5-bis(2methoxyethoxy)phenyl]-N,N-dimethylformamidine. Coupling of this formamidine with 3-ethynyl aniline gives erlotinib free base. On furthur treatment of this free base with methanolic/ethanolic hydrochloric acid gives us erlotinib hydrochloride.